Dr. Robert Davie joined Pharm-Olam in October 2019 as Chief Executive Officer. In this role, he leads Pharm-Olam's global workforce and business strategies supporting phase I-IV drug development programs for our biotech and pharmaceutical clients. Prior to joining Pharm-Olam, Dr. Davie worked at Covance, Inc. as Vice President and General Manager, Global Clinical Development. In this role, he was responsible for the oversight and delivery of clinical operations in more than 60 countries and with more than 6,000 staff under his leadership. Prior to joining Covance, Rob Worked at Procter & Gamble in OTC Healthcare in the clinical management of a number of different therapeutic areas. His experience includes registration, MOA and marketing studies. Rob began his career in basic science, particularly in GI physiology studying metal ion transport, and the transport of bile acids in patients with inflammatory bowel disease. Rob holds a bachelor’s degree from the University of Wolverhampton and a PhD in gastrointestinal absorption from the Council for National Academic Awards in the UK.
March 23rd, 2020
The coronavirus (COVID-19) was recently declared a pandemic by the World Health Organization (WHO), and countries around the world are working to flatten their infection curve and forestall the transmission of this dangerous virus. At Pharm-Olam, we understand the impact that infectious diseases can have on individuals and communities, and we want to express our empathy to those who have been impacted. We are also doing our part to help reduce disease transmission while continuing to support research and the fight against infectious diseases like COVID-19.